速效胰岛素类似物与人胰岛素在胰岛素泵中的应用研究  

Application research of rapidly acting insulin aspart and human insulin in insulin pump therapy

作　　者：赵巧玲[1] 余天强[1] 邹汶兵[1] 赵妮[1] 

机构地区：[1]广西民族医院内分泌科,广西南宁530001

出　　处：《华夏医学》2012年第4期503-505,共3页Acta Medicinae Sinica

摘　　要：目的:探索速效胰岛素类似物-门冬胰岛素(诺和锐)与人胰岛素(优泌林R)治疗2型糖尿病的疗效特点、安全性。方法:选取2型糖尿病患者60例,随机分成A组和B组,每组30例患者,A组用诺和锐、B组用优泌林R作为泵用胰岛素进行CSII强化治疗。结果:经过治疗,两组空腹血糖、餐后2h血糖均有显著降低,与治疗前比较差异有统计学意义(P<0.05);A和B组血糖达标时间分别为(4.20±1.86)d和(6.28±1.89)d,门冬胰岛素组达标时间较短(P<0.05);控制血糖达标时,胰岛素用量显著低于优泌林R组(P<0.05);诺和锐的用量较优泌林R的用量少,低血糖发生率较优泌林R组低。结论:门冬胰岛素是一种有效的抗糖尿病药物。Objective： To compare the effectiveness,security and application characteristics of rapidly acting insulin analogues（aspart） and human insulin（Humulin R） used in insulin pump in treating type 2 diabetes.Methods： Collected 60 type 2 diabetic patients and randomly divided into 2 groups with 30 patients in each group.Group A was treated with insulin aspart and group B with Humulin R.Results： After treatment,the fasting blood glucose and 2 hour post-meal blood sugar significantly decreased in the two groups（P〈0.05）.Compared with the group B,the treatment of insulin aspart shortened the therapeutic time（4.20±1.86d vs 6.28±1.89d）,reduced the amount of insulin dose in blood glucose control and the daily insulin dosage（P〈0.05）.The hypoglycemia incidence in group A was significantly lower than that in group B.Conclusion： Insulin aspart is a kind of effective anti-diabetic drug in CSII therapy.

关 键 词：门冬胰岛素 人胰岛素 胰岛素泵 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]